Status:
UNKNOWN
Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies
Lead Sponsor:
University of Virginia
Conditions:
Myelomeningocele
Neurogenic Bladder
Eligibility:
All Genders
Up to 18 years
Brief Summary
The investigators will assess the feasibility of replacing fluoroscopy/iodinated contrast with ultrasound/sulfur hexafluoride lipid-type A microspheres during routine urodynamic studies.
Detailed Description
Urodynamic studies routinely involve instillation of iohexol (OmnipaqueTM), a low osmolality contrast agent, into the bladder followed by fluoroscopic imaging to assess for reflux or variant anatomy o...
Eligibility Criteria
Inclusion
- Age 0-17
- Must have had prior urodynamic study at UVA
Exclusion
- Pregnant women (self-reported)
- Fetuses
- Neonates
- Prisoners
- Subjects with preexisting cardiac conditions (such as CHF and ventricular arrhythmias)
- Subjects with a known hypersensitivity to Lumason
Key Trial Info
Start Date :
March 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 2 2022
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT04738539
Start Date
March 2 2021
End Date
March 2 2022
Last Update
April 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Virginia
Charlottesville, Virginia, United States, 22911